聚乳酸基聚合物纳米颗粒介导的纳维托克拉克和地西他滨共同递送用于癌症治疗

IF 4.7 4区 医学 Q1 BIOTECHNOLOGY & APPLIED MICROBIOLOGY Nanomedicine: Nanotechnology, Biology and Medicine Pub Date : 2023-01-01 DOI:10.1016/j.nano.2022.102627
Neha Mehrotra PhD , Mohd Anees M.Sc , Sachchidanand Tiwari M.Tech , Surender Kharbanda PhD , Harpal Singh PhD
{"title":"聚乳酸基聚合物纳米颗粒介导的纳维托克拉克和地西他滨共同递送用于癌症治疗","authors":"Neha Mehrotra PhD ,&nbsp;Mohd Anees M.Sc ,&nbsp;Sachchidanand Tiwari M.Tech ,&nbsp;Surender Kharbanda PhD ,&nbsp;Harpal Singh PhD","doi":"10.1016/j.nano.2022.102627","DOIUrl":null,"url":null,"abstract":"<div><p><span><span><span><span>Combination chemotherapy<span> with systemic administration of </span></span>drugs in their free form can be challenging due to non-synchronized </span>pharmacokinetics and sub-optimal tumor accumulation. The present study investigates a PLA-based block copolymeric </span>nanocarrier<span> for the co-delivery of navitoclax and </span></span>decitabine<span><span><span> (NAV/DCB NPs) for combination cancer therapy. NAV/DCB NPs exhibited potent in vitro synergistic cytotoxicity in both acute myeloid leukemia<span> and breast cancer cell lines<span>. Biodistribution studies of NAV/DCB NPs in tumor bearing mice, showed significant drug accumulation in tumor tissue and detectable quantities in plasma even after 48 h. Good </span></span></span>hemocompatibility<span><span> with reduced in vivo platelet toxicity indicated that encapsulation in PLA-based nanocarrier helped ameliorate navitoclax associated thrombocytopenia<span>. In vivo biological activity of NAV/DCB NPs evaluated in </span></span>xenograft<span> AML and </span></span></span>syngeneic<span> breast cancer model, demonstrated potent tumor growth inhibition efficacy. PLA-based NAV/DCB dual NPs present a novel, safe and effective nanoformulation for combination cancer therapy in both solid tumors<span> and hematologic malignancies.</span></span></span></p></div>","PeriodicalId":396,"journal":{"name":"Nanomedicine: Nanotechnology, Biology and Medicine","volume":"47 ","pages":"Article 102627"},"PeriodicalIF":4.7000,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"2","resultStr":"{\"title\":\"Polylactic acid based polymeric nanoparticle mediated co-delivery of navitoclax and decitabine for cancer therapy\",\"authors\":\"Neha Mehrotra PhD ,&nbsp;Mohd Anees M.Sc ,&nbsp;Sachchidanand Tiwari M.Tech ,&nbsp;Surender Kharbanda PhD ,&nbsp;Harpal Singh PhD\",\"doi\":\"10.1016/j.nano.2022.102627\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><p><span><span><span><span>Combination chemotherapy<span> with systemic administration of </span></span>drugs in their free form can be challenging due to non-synchronized </span>pharmacokinetics and sub-optimal tumor accumulation. The present study investigates a PLA-based block copolymeric </span>nanocarrier<span> for the co-delivery of navitoclax and </span></span>decitabine<span><span><span> (NAV/DCB NPs) for combination cancer therapy. NAV/DCB NPs exhibited potent in vitro synergistic cytotoxicity in both acute myeloid leukemia<span> and breast cancer cell lines<span>. Biodistribution studies of NAV/DCB NPs in tumor bearing mice, showed significant drug accumulation in tumor tissue and detectable quantities in plasma even after 48 h. Good </span></span></span>hemocompatibility<span><span> with reduced in vivo platelet toxicity indicated that encapsulation in PLA-based nanocarrier helped ameliorate navitoclax associated thrombocytopenia<span>. In vivo biological activity of NAV/DCB NPs evaluated in </span></span>xenograft<span> AML and </span></span></span>syngeneic<span> breast cancer model, demonstrated potent tumor growth inhibition efficacy. PLA-based NAV/DCB dual NPs present a novel, safe and effective nanoformulation for combination cancer therapy in both solid tumors<span> and hematologic malignancies.</span></span></span></p></div>\",\"PeriodicalId\":396,\"journal\":{\"name\":\"Nanomedicine: Nanotechnology, Biology and Medicine\",\"volume\":\"47 \",\"pages\":\"Article 102627\"},\"PeriodicalIF\":4.7000,\"publicationDate\":\"2023-01-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"2\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Nanomedicine: Nanotechnology, Biology and Medicine\",\"FirstCategoryId\":\"1\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S1549963422001137\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"BIOTECHNOLOGY & APPLIED MICROBIOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Nanomedicine: Nanotechnology, Biology and Medicine","FirstCategoryId":"1","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1549963422001137","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"BIOTECHNOLOGY & APPLIED MICROBIOLOGY","Score":null,"Total":0}
引用次数: 2

摘要

由于非同步的药代动力学和次优的肿瘤积累,联合化疗与全身自由形式的药物管理可能具有挑战性。本研究研究了一种基于pla的嵌段共聚物纳米载体,用于联合递送navitoclax和地西他滨(NAV/DCB NPs)用于联合癌症治疗。NAV/DCB NPs在急性髓性白血病和乳腺癌细胞系中均表现出强大的体外协同细胞毒性。NAV/DCB NPs在荷瘤小鼠体内的生物分布研究显示,即使在48小时后,NAV/DCB NPs在肿瘤组织中也有明显的药物积累,血浆中也有可检测到的药物量。良好的血液相容性和体内血小板毒性降低表明,pla纳米载体的包封有助于改善navitoclax相关的血小板减少。NAV/DCB NPs的体内生物活性在异种移植物AML和同基因乳腺癌模型中被评估,显示出强大的肿瘤生长抑制作用。基于pla的NAV/DCB双NPs为实体瘤和血液系统恶性肿瘤的联合治疗提供了一种新的、安全有效的纳米制剂。
本文章由计算机程序翻译,如有差异,请以英文原文为准。

摘要图片

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
Polylactic acid based polymeric nanoparticle mediated co-delivery of navitoclax and decitabine for cancer therapy

Combination chemotherapy with systemic administration of drugs in their free form can be challenging due to non-synchronized pharmacokinetics and sub-optimal tumor accumulation. The present study investigates a PLA-based block copolymeric nanocarrier for the co-delivery of navitoclax and decitabine (NAV/DCB NPs) for combination cancer therapy. NAV/DCB NPs exhibited potent in vitro synergistic cytotoxicity in both acute myeloid leukemia and breast cancer cell lines. Biodistribution studies of NAV/DCB NPs in tumor bearing mice, showed significant drug accumulation in tumor tissue and detectable quantities in plasma even after 48 h. Good hemocompatibility with reduced in vivo platelet toxicity indicated that encapsulation in PLA-based nanocarrier helped ameliorate navitoclax associated thrombocytopenia. In vivo biological activity of NAV/DCB NPs evaluated in xenograft AML and syngeneic breast cancer model, demonstrated potent tumor growth inhibition efficacy. PLA-based NAV/DCB dual NPs present a novel, safe and effective nanoformulation for combination cancer therapy in both solid tumors and hematologic malignancies.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
CiteScore
8.10
自引率
3.60%
发文量
104
审稿时长
4.6 months
期刊介绍: Nanomedicine: Nanotechnology, Biology and Medicine (NBM) is an international, peer-reviewed journal presenting novel, significant, and interdisciplinary theoretical and experimental results related to nanoscience and nanotechnology in the life and health sciences. Content includes basic, translational, and clinical research addressing diagnosis, treatment, monitoring, prediction, and prevention of diseases.
期刊最新文献
State-of-the-art and future perspectives in infertility diagnosis: Conventional versus nanotechnology-based assays Fabrication of blended nanofibrous cardiac patch transplanted with TGF-β3 and human umbilical cord MSCs-derived exosomes for potential cardiac regeneration after acute myocardial infarction Delivery of gene editing therapeutics Liposomes - Human phagocytes interplay in whole blood: effect of liposome design Coating influence on inner shell water exchange: An underinvestigated major contributor to SPIONs relaxation properties
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1